» Articles » PMID: 31578870

Mitochondrial Dysfunction at the Center of Cancer Therapy

Overview
Specialty Endocrinology
Date 2019 Oct 4
PMID 31578870
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondria undergo constant morphological changes through fusion, fission, and mitophagy. As the key organelle in cells, mitochondria are responsible for numerous essential cellular functions such as metabolism, regulation of calcium (Ca), generation of reactive oxygen species, and initiation of apoptosis. Unsurprisingly, mitochondrial dysfunctions underlie many pathologies including cancer. Currently, the gold standard for cancer treatment is chemotherapy, radiation, and surgery. However, the efficacy of these treatments varies across different cancer cells. It has been suggested that mitochondria may be at the center of these diverse responses. In the past decade, significant advances have been made in understanding distinct types of mitochondrial dysfunctions in cancer. Through investigations of underlying mechanisms, more effective treatment options are developed. We summarize various mitochondria dysfunctions in cancer progression that have led to the development of therapeutic options. Current mitochondrial-targeted therapies and challenges are discussed. To address the "root" of cancer, utilization of mitochondrial-targeted therapy to target cancer stem cells may be valuable. Investigation of other areas such as mitochondrial trafficking may offer new insights into cancer therapy. Moreover, common antibiotics could be explored as mitocans, and synthetic lethality screens can be utilized to overcome the plasticity of cancer cells.

Citing Articles

Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis.

Bi Q, Nie J, Wu Q, Sun L, Zhu S, Bai J Med Oncol. 2025; 42(3):60.

PMID: 39891862 DOI: 10.1007/s12032-025-02604-9.


A Multi-Omics Analysis of a Mitophagy-Related Signature in Pan-Cancer.

Agir N, Georgakopoulos-Soares I, Zaravinos A Int J Mol Sci. 2025; 26(2.

PMID: 39859167 PMC: 11765132. DOI: 10.3390/ijms26020448.


Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention.

Pagano G, Lyakhovich A, Thomas P, Catalayud F, Tiano L, Zatterale A Inflammopharmacology. 2024; 33(2):431-441.

PMID: 39656417 DOI: 10.1007/s10787-024-01613-w.


Bufotalin Induces Oxidative Stress-Mediated Apoptosis by Blocking the ITGB4/FAK/ERK Pathway in Glioblastoma.

Tan J, Lin G, Zhang R, Wen Y, Luo C, Wang R Antioxidants (Basel). 2024; 13(10).

PMID: 39456433 PMC: 11505062. DOI: 10.3390/antiox13101179.


Targeting ROS in cancer: rationale and strategies.

Glorieux C, Liu S, Trachootham D, Huang P Nat Rev Drug Discov. 2024; 23(8):583-606.

PMID: 38982305 DOI: 10.1038/s41573-024-00979-4.